Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 3/20 | 0.65 |
| ▸ | DRD2 | P14416 | 2/20 | 0.63 |
| ▸ | DRD5 | P21918 | 1/20 | 0.63 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.58 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.57 |
| ▸ | PRCP | P42785 | 2/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18634398 | 0.85 | CHRNA7 (0.53) | DRD1DRD2DRD5CHRNA7ADRA1D | |
| SCHEMBL13503895 | 0.84 | PRCP (0.54) | DRD1DRD2DRD5PRCP | |
| SCHEMBL6161969 | 0.82 | TAAR1 (0.58) | DRD1DRD2DRD5ADRA1DADRA1A | |
| SCHEMBL14223373 | 0.81 | DRD1 (0.51) | DRD1DRD2DRD5CHRNA7ADRA1D | |
| SCHEMBL8254879 | 0.81 | DRD1 (0.48) | DRD1DRD2DRD5CHRNA7PRCP | |
| SCHEMBL10753534 | 0.78 | CHRNA7 (0.82) | CHRNA7TAAR1 | |
| SCHEMBL3263639 | 0.78 | DRD1 (0.46) | DRD1DRD2DRD5ADRA1DADRA1A | |
| SCHEMBL13503890 | 0.78 | DRD1 (0.49) | DRD1DRD2DRD5PRCP | |
| SCHEMBL8476976 | 0.77 | RET (0.51) | DRD1DRD2DRD5CHRNA7PRCP | |
| SCHEMBL13503801 | 0.77 | OPRM1 (0.48) | DRD1DRD2DRD5PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252752-B2 | An amidation product of ribosyl or glucosyl saccharide and a dopamine or derivative (forms amide through amine and carboxylic group); useful for treating neurological diseases including Parkinson's | GLYCON LLC (US) | 2012-08-28 | — | — | US | disclosed |
| EP-1385857-B1 | PHARMACEUTICAL DOPAMINE GLYCOCONJUGATE COMPOSITIONS AND METHODS OF THEIR PREPARATION | INTERNAT MEDICAL INNOVATIONS I (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20080194802-A1 | PHARMACEUTICAL DOPAMINE GLYCOCONJUGATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE | GLYCON LLC | 2008-08-14 | — | — | US | disclosed |
| US-7345031-B2 | Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation and use | INTERNATIONAL MEDICAL INNOVATIONS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20060217394-A1 | Treatment of anhedonia | SILVAN S. TOMKINS INSTITUTE, INC. | 2006-09-28 | — | — | US | disclosed |
| EP-1385857-A4 | PHARMACEUTICAL DOPAMINE GLYCOCONJUGATE COMPOSITIONS AND METHODS OF THEIR PREPARATION | INTERNAT MEDICAL INNOVATIONS I (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2006091725-A1 | TREATMENT OF ANHEDONIA | THE SILVAN S. TOMKINS INSTITUTE (US) | 2006-08-31 | — | — | WO | disclosed |
| US-20050250739-A1 | Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation and use | GLYCON LLC | 2005-11-10 | — | — | US | disclosed |
| EP-1385857-A1 | PHARMACEUTICAL DOPAMINE GLYCOCONJUGATE COMPOSITIONS AND METHODS OF THEIR PREPARATION | International Medical Innovations, Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| US-6548484-B1 | An amidation product of ribosyl or glucosyl saccharide and a dopamine or derivative ( forms a amide through amine and carboxylic group); useful for treating neurological diseases including Parkinson's and related diseases | INTERNATIONAL MEDICAL INNOVATIONS, INC. | 2003-04-15 | — | — | US | disclosed |
| WO-2001079244-A1 | PHARMACEUTICAL DOPAMINE GLYCOCONJUGATE COMPOSITIONS AND METHODS OF THEIR PREPARATION | INTERNATIONAL MEDICAL INNOVATIONS, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194802-A1 | PHARMACEUTICAL DOPAMINE GLYCOCONJUGATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE | SLC6A3, SLC2A3, SLC2A1 | DRD1 72/4885DRD2 28/4885DRD5 205/4885 |
| US-20050250739-A1 | Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation and use | SLC6A3, SLC2A3, SLC2A1 | DRD1 69/4885DRD2 30/4885DRD5 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.